You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Multiple Myeloma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Smoldering Multiple Myeloma Trial (Selinexor)

Not yet recruiting
  • Smoldering Multiple Myeloma
  • (no location specified)
Oct 27, 2022

High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,

Recruiting
  • High-risk Smoldering Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Aug 11, 2022

Health Technology Intervention on Patient Activation in Multiple

Not yet recruiting
  • Multiple Myeloma in Relapse
  • +3 more
    • (no location specified)
    Jan 9, 2023

    Multiple Myeloma Trial (Teclistamab, Daratumumab, Lenalidomide)

    Not yet recruiting
    • Multiple Myeloma
    • (no location specified)
    Oct 6, 2022

    Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)

    Withdrawn
    • Relapsed Multiple Myeloma
    • Refractory Multiple Myeloma
    • Rapid Infusion Isatuximab
    • (no location specified)
    Jul 3, 2022

    Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Aug 8, 2022

    Two Biologically and Clinically Distinct Entities: Progressive

    Recruiting
    • Multiple Myeloma
    • +2 more
      • Miami, Florida
        University of Miami Hospitals
      Jun 7, 2022

      Multiple Myeloma Trial in Boston, Milwaukee (CART-ddBCMA)

      Not yet recruiting
      • Multiple Myeloma
      • CART-ddBCMA
      • Boston, Massachusetts
      • +1 more
      Jul 7, 2022

      Host Microbiota and Il-17 in Favoring Multiple Myeloma

      Recruiting
      • Multiple Myeloma
        • Milan, Milano, Italy
          IRCCS Ospedale San Raffaele
        Jan 26, 2023

        Selinexor, Daratumumab and Dexamethasone in Chinese Multiple

        Not yet recruiting
        • Multiple Myeloma at First Relapse
          • (no location specified)
          Sep 27, 2022

          Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

          Recruiting
          • Relapse Multiple Myeloma
          • Refractory Multiple Myeloma
          • BCMA Targeted CAR T-cells
          • Hangzhou, Zhejiang, China
            The First Affiliated Hospital, Medical College, Zhejiang Univers
          Jun 18, 2022

          Using Mass Spectrometry Detecting Minimal Residual Disease in

          Recruiting
          • Multiple Myeloma
            • Tianjin, China
              InsituteHBDH
            Sep 8, 2022

            Based on Maintenance Therapy Post Autologous Stem Cell

            Recruiting
            • Multiple Myeloma
            • Autologous Stem Cell Transplant
            • +2 more
            • Tampa, Florida
              Moffitt Cancer Center
            Jul 27, 2022

            Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)

            Active, not recruiting
            • Smoldering Multiple Myeloma
            • Boston, Massachusetts
              Dana Farber Cancer Institute
            Mar 15, 2022

            Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))

            Withdrawn
            • Relapsed Multiple Myeloma
            • Refractory Multiple Myeloma
            • Elotuzumab, Selinexor, and Dexamethasone (ESd)
            • (no location specified)
            Apr 27, 2022

            Serum NGAL IN Patients With Multiple Myeloma

            Not yet recruiting
            • Multiple Myeloma(MM)
            • SERUM NGAL
            • (no location specified)
            Jun 26, 2022

            Multiple Myeloma Trial in Philadelphia (Coordinated Financial Navigation Program)

            Recruiting
            • Multiple Myeloma
            • Coordinated Financial Navigation Program
            • Philadelphia, Pennsylvania
              Penn Medicine
            Jul 12, 2022

            Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)

            Not yet recruiting
            • Multiple Myeloma
            • +4 more
            • Pembrolizumab
            • San Francisco, California
              University of California, San Francisco
            Mar 23, 2022

            Multiple Myeloma Trial (Cilta-cel OOS Therapy)

            Available
            • Multiple Myeloma
            • Cilta-cel OOS Therapy
            • (no location specified)
            Aug 15, 2022

            Solid Tumors, Adult, Multiple Myeloma, Lymphoma Trial in San Antonio (VP301)

            Recruiting
            • Solid Tumors, Adult
            • +2 more
            • San Antonio, Texas
              NEXT Oncology
            Jan 16, 2023

            Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)

            Recruiting
            • Multiple Myeloma
            • Beverly Hills, California
              Beverly Hills Cancer Center
            Dec 21, 2022

            Thrombosis in Multiple Myeloma in an University Medical Center

            Recruiting
            • Multiple Myeloma
            • +2 more
            • Multiple myeloma
            • Groningen, Netherlands
              University Medical Center Groningen
            Sep 12, 2022

            Multiple Myeloma, New Diagnosis Tumor Trial in Hangzhou (BCMA CAR-T cells)

            Recruiting
            • Multiple Myeloma
            • New Diagnosis Tumor
            • BCMA CAR-T cells
            • Hangzhou, Zhejiang, China
              The First Affiliated Hospital, College of Medicine, Zhejiang Uni
            Jan 31, 2023

            Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (MCARH125, MCARH109)

            Recruiting
            • Multiple Myeloma
            • +2 more
            • MCARH125
            • MCARH109
            • New York, New York
              Memorial Sloan Kettering Cancer Center
            Jun 20, 2022

            Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

            Recruiting
            • Refractory Multiple Myeloma
            • Relapsed Multiple Myeloma
            • Manufactured Anti-BCMA CAR-T cells
            • +2 more
            • San Francisco, California
              University of California, San Francisco
            Jan 6, 2023